ClinicalTrials.gg
RecruitingNCT06456073Updated Apr 8, 2026

E-CEL UVEC Treatment for Anal Fissures

A Phase 1 interventional study of E-CEL UVEC cells (AB-207) in Chronic Anal Fissure, sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Weill Medical College of Cornell University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial is being conducted by investigators who are colorectal surgeons. Eligible study participants will receive the experimental treatment E-CEL UVEC cells by direct injection into the anal fissure. The study is being conducted to determine if E-CEL UVEC cell injections will be safe and would have any effects on healing of the anal fissure.

Read the detailed description

This Phase 1b trial is conducted to evaluate the initial safety and efficacy of local (percutaneous) injections of E-CEL UVEC cells, genetically-engineered (pro-survival gene, E4ORF1+), human umbilical vein endothelial cells, as an experimental treatment of patients with chronic anal fissure (CAF) who have failed medical therapy (i.e., topical vasodilators ± botulinum injection). The study is a non-randomized, open-label, single arm study, meaning every study participant will receive some dose of the experimental study drug (no placebo). Consented, eligible participants will receive percutaneous injections of E-CEL UVEC cell product along the sides of the fissure; the treatments are spaced 3 to 4 weeks apart. Initial safety and efficacy parameters will be observed over a 6-month period, followed by a long-term follow-up consisting of annual questionnaire provided by electronic means.

This research study is being done because, in animal studies, E-CEL UVEC cells have been shown to aid in restoring or accelerating the normal healing in various tissues. This study will test if it is safe to use E-CEL UVEC cell therapy and if they it would aid in restoring or improve healing of CAF that was not responding to medical therapy. Improvement of CAF would be assessed in a standard, clinical manner (using brief digital palpation by the doctor), a method acceptable to the FDA, versus the original method (detailed quantitative photo-documentation). This study is being led by Dr. Kelly Garrett, Associate Professor of Surgery, and conducted by surgeons in the Colon and Rectal Surgery Division of Weill Cornell Medical College.

02

Conditions studied

  • Chronic Anal Fissure

Browse trials for

Keywords

  • Chronic Anal Fissure
03

In context

Fissure in Ano

84 studies on the registry are indexed under Fissure in Ano; 16 are open to participants now.

This study's planned enrollment of 20 is below the median of 99 across 65 interventional studies indexed under Fissure in Ano.

Browse Fissure in Ano studies →

Lead sponsor

Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.

Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults 18 years and older
  2. Anterior or posterior chronic anal fissure (CAF) - chronicity defined as presence of anal fissure ≥ 6 weeks
  3. Inadequate response to medical treatment of anal fissure (1 month of failed vasodilator treatment plus declined or failed botulinum injection treatment)
  4. Recent history of pain on defecation at a level 4 or higher on the numerical rating scale (NRS)
  5. Vital signs upon screening:

    • Blood pressure: systolic ≥ 90 and \< 140; and diastolic ≥ 60 and \< 90.
    • Breathing: ≥ 12 and ≤ 20 breaths per minute.
    • Pulse: ≥ 60 and ≤ 100 beats per minute.
    • Temperature: ≥ 97.8°F and ≤ 99.1°F (36.5°C to 37.3°C)
    • O2 saturation: > 92%
  6. Willing to take adequate measures
  7. Willing to sign an form and follow instructions for the trial including appearing for visits and filling out questionnaires

Exclusion criteria

Exclusion Criteria:

  1. Lateral anal fissure
  2. Presence of peri-anal or rectovaginal fistula, rectal or anal stenosis, or peri-anal abscess or non-healing peri-anal post-surgical wounds that are not anal fissures (subjects with history of anorectal surgery with healed surgical wound is not excluded)
  3. Active, untreated or medically unresponsive infection of the anal fissure or fistula (e.g., erythema and pus)
  4. Active systemic infection (e.g., bacteremia, sepsis) - stable, controlled and treated + subjects (e.g., recent plasma HIV RNA \<200 copies/mL) are not excluded
  5. Presence of inflammatory bowel diseases (e.g., Crohn's, ulcerative colitis)
  6. Taking systemic chemotherapy or local pelvic radiation treatments
  7. Renal impairment defined by serum creatinine ≥ 1.5 x upper limit of normality ()
  8. Hepatic impairment defined by both of the following laboratory ranges:

    (a) total ≥ 1.5 x ULN unless benign congenital hyperbilirubinemia; and (b) (AST) and alanine aminotransferase (ALT) ≥ 2.5 x ULN

  9. Active alcohol or substance use that, in the opinion of the site investigator, will interfere with study follow-up.
  10. Active malignant tumor (tumors must be in remission for ≥ 6 months without maintenance chemotherapy and/or radiation)
  11. Ongoing or recent history (within 6 months) of abnormal, severe, progressive, or uncontrolled hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases
  12. Congenital immunodeficiencies
  13. History of major surgery or severe trauma within the previous 3 months
  14. Subjects who are actively being considered as candidates for solid organ transplantation or who may have a high likelihood of needing a solid organ transplant (ex. Progressive heart failure)
  15. Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed during the study (180 days)
  16. Subjects who have known or documented allergy to DMSO
  17. Subjects who do not wish to or cannot comply with study procedures
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Local percutaneous injection of E-CEL UVEC cells around the anal fissure

    Biological: E-CEL UVEC cells (AB-207)

Interventions

  • BiologicalE-CEL UVEC cells (AB-207)

    Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)

06

What researchers measure

Primary outcomes

  1. Number of severe injection site reactions

    Severe refers to Grade ≥ 3 as per CTCAE v5.0 terms and grading

    Time frame: Up to 180 days

  2. Number of severe injection site reactions that are serious adverse events related to IP

    Time frame: Up to 180 days

  3. Proportion of treated responders

    Treated responders defined as absence of the anal fissure with digital (e.g., index finger) palpation by investigator (supplemented by photo-documentation whenever possible) from baseline

    Time frame: Up to 180 days

Secondary outcomes

  1. Changes in severity of pain on defecation (NRS) from (Day 0) baseline

    Based on Numerical Rating Scale (NRS) measures at timepoints compared to baseline. Scale ranges from 0-10 with 0 representing no pain and severity of pain increasing chronologically.

    Time frame: Days 0, 14, 21, 28, 42, 56, 90 and 180

  2. Proportion of treated responders

    Treated responders defined as absence of the anal fissure with digital (e.g., index finger) palpation by investigator (supplemented by photo-documentation whenever possible) from baseline (Day 0)

    Time frame: Days 14, 21, 28, 42, 56, 90 and 180

  3. Change in proportion of subjects

    Subjects with ≥ 50% reduction in pain-on-defecation (NRS) from baseline (Day 0)

    Time frame: Days 0, 14, 21, 28, 42, 56, 90 and 180

  4. Proportion of treated subjects who have complete cessation of fissure-related symptoms

    Time frame: Up to 180 days

  5. Median percent change in fissure-wound from baseline (Day 0)

    Median percent change in fissure wound size based on mm\^2 using digital photo-image analysis

    Time frame: Days 0, 14, 21, 28, 42, 56, 90 and 180

  6. Mean percent change in fissure-wound from baseline (Day 0)

    Mean percent change in fissure wound size based on mm\^2 using digital photo-image analysis

    Time frame: Days 0, 14, 21, 28, 42, 56, 90 and 180

  7. Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)

    Time frame: Day 14

  8. Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)

    Time frame: Day 21

  9. Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)

    Time frame: Day 28

  10. Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)

    Time frame: Day 42

  11. Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)

    Time frame: Day 56

  12. Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)

    Time frame: Day 90

  13. Proportion of treated subjects who have ≥ 50% wound closure from baseline (Day 0)

    Time frame: Day 180

  14. Time-to-response in days in treated responders

    Treated responders are defined as those with ≥50% reduction in pain on defecation (using numerical rating scale (NRS)) and ≥50% reduction in fissure-wound area from baseline (Day 0).

    Time frame: Up to 180 days

  15. Time-to symptom improvement in days in treated subjects who achieved symptom improvement

    Symptom improvement is defined as a minimum 50% reduction in pain-on defecation (using numerical rating scale (NRS)) in treated subjects.

    Time frame: Up to 180 days

  16. Time-to 50% wound closure in days in subjects who achieved at least 50% wound closure

    Time frame: Up to 180 days

  17. Time-to complete wound closure in days in subjects who achieved complete wound closure

    Time frame: Up to 80

  18. Cumulative number of severe adverse events, defined and graded by NCI CTCAE v5.0

    Time frame: Up to 180 days

  19. Percent of serious adverse events, including relatedness category

    Percent of SAE and relatedness categories of SAE as defined and graded by NCI CTCAE v5.0

    Time frame: Up to 180 days

  20. Percent of treatment-emergent adverse events per system organ class (SOC)

    Time frame: Up to 180 days

  21. Proportion of fissure relapse in treated subjects

    Fissure relapse is defined as worsening of pain and increase in size after healing.

    Time frame: Up to 180 days

  22. Time-to-relapse in days in subjects who experienced relapse

    Days to relapse from time of healing.

    Time frame: Up to 180 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 13, 2024
StartActual
Sep 12, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06456073
Collaborators
Angiocrine Bioscience
Responsible party
Sponsor
First posted
Jun 13, 2024
Start date
Sep 12, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 8, 2026

Study contacts

Kelly Garrett, MD
Contact
keg9034@med.cornell.edu
646-962-2270
KM Muktasid
Contact
kmm4010@med.cornell.edu
646-962-2789
Kelly Garrett, MD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion